AviadoBio Overview

  • Founded
  • 2019
Founded
  • Status
  • Private
  • Employees
  • 20
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $108M
Latest Deal Amount
  • Investors
  • 8

AviadoBio General Information

Description

Developer of transformative gene therapies for diseases designed to transform the lives of people living with neurodegenerative disorders. The company's platform combines next-generation gene therapy design with deep neuroscience expertise and a novel neuroanatomy-led approach to drug delivery, thereby maximizing the therapeutic potential for patients living with devastating neurological diseases and helping in the treatment of the disease.

Contact Information

Website
www.aviadobio.com
Formerly Known As
NeuroGeneUs Ltd
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 86 Hatton Garden
  • Fifth Floor
  • London EC1N 8QQ
  • England, United Kingdom

AviadoBio Timeline

202020212022
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AviadoBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 02-Dec-2021 $108M 00000 Completed Startup
1. Seed Round 16-Sep-2020 000.00 000.00 0000 Completed Stealth
To view AviadoBio’s complete valuation and funding history, request access »

AviadoBio Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series Seed preferred 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view AviadoBio’s complete cap table history, request access »

AviadoBio Executive Team (6)

Name Title Board Seat Contact Info
Lisa Deschamps Chief Executive Officer & Board Member
Jonathan Jones Chief Operating Officer
Christopher Shaw Co-Founder and Chief Scientific and Clinical Advisor
Youn Lee Co-Founder and Head of Discovery
Do Lee Co-Founder and Head of Vector Sciences
You’re viewing 5 of 6 executive team members. Get the full list »

AviadoBio Board Members (8)

Name Representing Role Since
Amber Salzman Ph.D Self Board Member 000 0000
Jeanne Bolgar AviadoBio Chairperson 000 0000
Lisa Deschamps AviadoBio Chief Executive Officer & Board Member 000 0000
Matthew McAviney MD F-Prime Capital Board Member 000 0000
Nihal Sinha MD Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

AviadoBio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AviadoBio Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
EQT Life Sciences Venture Capital Minority 000 0000 000000 0
Monograph Capital Other Minority 000 0000 000000 0
New Enterprise Associates Venture Capital Minority 000 0000 000000 0
Advent Life Sciences Venture Capital Minority 000 0000 000000 0
Dementia Discovery Fund Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial